“CSL has an outstanding track record over the long term,” said David Grace of the Australian Foundation Investment Company, which owns about A$629 million of the company’s shares and has been invested ...
Cognition Therapeutics (CGTX) provided an update on a biomarker analysis from the Phase 2 ‘SHINE’ study in mild-to-moderate Alzheimer’s disease. This new analysis focused on plasma samples from all ...
Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...